Cell surface membrane proteins as personalized biomarkers: Where we stand and where we are headed

Biomarkers in Medicine

Volumn 7, Issue 5, 2013, Pages 803-819

  Várady, György ^a,b   Cserepes, Judit ^b   Németh, Adrienn ^b   Szabó, Edit ^b   Sarkadi, Balázs ^a,b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c National Blood Service   (Hungary)

Author keywords

cluster of differentiation markers; erythrocyte membrane proteins as biomarkers; membrane channels; membrane protein biomarkers; membrane receptors; membrane transporters; processing of membrane proteins; trafficking of membrane proteins

Indexed keywords

ABC TRANSPORTER; BIOLOGICAL MARKER; CARRIER PROTEIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD340 ANTIGEN; CD4 ANTIGEN; CD52 ANTIGEN; CD6 ANTIGEN; CD75 ANTIGEN; CELL MEMBRANE PROTEIN; ERYTHROCYTE MEMBRANE PROTEIN; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEMBRANE RECEPTOR; MULTIDRUG RESISTANCE PROTEIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG;

CELL DIFFERENTIATION; CELL PROLIFERATION; ERYTHROCYTE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE METABOLISM; FLOW CYTOMETRY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MUTATIONAL ANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; QUANTITATIVE ANALYSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; DIAGNOSIS; DISEASE; HEALTH; HUMANS; INDIVIDUALIZED MEDICINE; MEMBRANE PROTEINS;

EID: 84884557714     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.90     Document Type: Review

References (93)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 141(7), 1117-1134 (2010
2. Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 70(10), 3857-3860 (2010
3. Traxler P. Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin. Ther. Targets 7(2), 215-234 (2003
4. Singleton KR, Kim J, Hinz TK et al. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol. Pharmacol. 83(4), 882-893 (2013
5. Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: Present and future role in gastrointestinal cancer treatment: A review. Oncologist 11(6), 602-611 (2006
6. Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE 7(10), e44372 (2012
7. Lidgren M, Wilking N, Jonsson B, Rehnberg C. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol. 47(6), 1018-1028 (2008
8. Lundstrom K. An overview on GPCRs and drug discovery: Structure-based drug design and structural biology on GPCRs. Methods Mol. Biol. 552, 51-66 (2009
9. Stevens RC, Cherezov V, Katritch V et al. The GPCR Network: A large-scale collaboration to determine human GPCR structure and function. Nat. Rev. Drug Discov. 12(1), 25-34 (2013
10. Salon JA, Lodowski DT, Palczewski K. The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol. Rev. 63(4), 901-937 (2011
11. Harrison C. Muddy waters for authorized generics. Nat. Rev. Drug Discov. 5(8), 624-625 (2006
12. Congreve M, Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharmacol. 159(5), 986-996 (2010
13. Catterall WA. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 26(1), 13-25 (2000
14. Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiol. Rev. 82(3), 769-824 (2002
15. Keramidas A, Moorhouse AJ, Schofield PR, Barry PH. Ligand-gated ion channels: Mechanisms underlying ion selectivity. Prog. Biophys. Mol. Biol. 86(2), 161-204 (2004
16. Zamponi GW. Welcome to 'ion channels: Key therapeutic targets'. Future Med. Chem. 2(5), 689-690 (2010
17. Moss AJ, Kass RS. Long QT syndrome: From channels to cardiac arrhythmias. J. Clin. Invest. 115(8), 2018-2024 (2005
18. Morita H, Wu J, Zipes DP. The QT syndromes: Long and short. Lancet 372(9640), 750-763 (2008
19. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. 33(6), 453-458 (2001
20. Dean M. The genetics of ATP-binding cassette transporters. Methods Enzymol. 400, 409-429 (2005
21. Cooper MA. Advances in membrane receptor screening and analysis. J. Mol. Recognit. 17(4), 286-315 (2004
22. De Meyts P. The insulin receptor: A prototype for dimeric, allosteric membrane receptors? Trends Biochem. Sci. 33(8), 376-384 (2008
23. Palmgren MG, Nissen P. P-type ATPases. Annu. Rev. Biophys. 40, 243-266 (2011
24. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71, 537-592 (2002
25. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol. Rev. 86(4), 1179-1236 (2006
26. Hediger MA, Clemencon B, Burrier RE, Bruford EA. The ABCs of membrane transporters in health and disease (SLC series): Introduction. Mol. Aspects Med. 34(2-3), 95-107 (2013
27. Yee SW, Chen L, Giacomini KM. Pharmacogenomics of membrane transporters: Past, present and future. Pharmacogenomics 11(4), 475-479 (2010
28. Degorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52, 249-273 (2012
29. Emery AE. The muscular dystrophies. Lancet 359(9307), 687-695 (2002
30. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment. EMBO Rep. 5(9), 872-876 (2004
31. Jaeken J, Carchon H. Congenital disorders of glycosylation: A booming chapter of pediatrics. Curr. Opin. Pediatr. 16(4), 434-439 (2004
32. Rosnoblet C, Peanne R, Legrand D, Foulquier F. Glycosylation disorders of membrane trafficking. Glycoconj. J. 30(1), 23-31 (2013
33. Woods AG, Woods CW, Snow TM. Congenital disorders of glycosylation. Adv. Neonatal Care 12(2), 90-95 (2012
34. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 339(1), 269-280 (2010
35. Kim C, Ye F, Ginsberg MH. Regulation of integrin activation. Annu. Rev. Cell Dev. Biol. 27, 321-345 (2011
36. Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 1, 154-188 (2011
37. Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 283181 (2012
38. Naci D, El Azreq MA, Chetoui N et al. a2b1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J. Biol. Chem. 287(21), 17065-17076 (2012
39. Menichella DM, Goodenough DA, Sirkowski E, Scherer SS, Paul DL. Connexins are critical for normal myelination in the CNS. J. Neurosci. 23(13), 5963-5973 (2003
40. Dbouk HA, Mroue RM, El-Sabban ME, Talhouk RS. Connexins: A myriad of functions extending beyond assembly of gap junction channels. Cell. Commun. Signal. 7, 4 (2009
41. El-Benna J, Dang PM, Gougerot-Pocidalo MA, Marie JC, Braut-Boucher F. p47phox, the phagocyte NADPH oxidase/NOX2 organizer: Structure, phosphorylation and implication in diseases. Exp. Mol. Med. 41(4), 217-225 (2009
42. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 1820(7), 940-948 (2012
43. Glick BS, Nakano A. Membrane traffic within the Golgi apparatus. Annu. Rev. Cell Dev. Biol. 25, 113-132 (2009
44. MacGurn JA, Hsu PC, Emr SD. Ubiquitin and membrane protein turnover: From cradle to grave. Annu. Rev. Biochem. 81, 231-259 (2012
45. Beguin P, Hasler U, Staub O, Geering K. Endoplasmic reticulum quality control of oligomeric membrane proteins: Topogenic determinants involved in the degradation of the unassembled Na,K-ATPase a subunit and in its stabilization by b subunit assembly. Mol. Biol. Cell 11(5), 1657-1672 (2000
46. Sakamoto A, Matsumaru T, Yamamura N et al. Quantitative expression of human drug transporter proteins in lung tissues: Analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J. Pharm. Sci. 102(9), 3395-3406 (2013
47. Ohtsuki S, Ikeda C, Uchida Y et al. Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Mol. Pharm. 10(1), 289-296 (2013
48. Lai X. Reproducible method to enrich membrane proteins with high purity and high yield for an LC-MS/MS approach in quantitative membrane proteomics. Electrophoresis 34(6), 809-817 (2013
49. Bernard A, Brottier P, Georget E, Lepage V, Boumsell L. Joint report of the first international workshop on human leucocyte differentiation antigens by the investigators of the participating laboratories. In: Leucocyte Typing I. Bernard A et al. (Eds). Springer Verlag, Germany, 9-135 (1984
50. Zola H, Swart B, Banham A et al. CD molecules 2006-human cell differentiation molecules. J. Immunol. Methods 319(1-2), 1-5 (2007
51. Zola H, Swart B, Nicholson I et al. CD molecules 2005: Human cell differentiation molecules. Blood 106(9), 3123-3126 (2005
52. Zola H, Swart B. The human leucocyte differentiation antigens (HLDA) workshops: The evolving role of antibodies in research, diagnosis and therapy. Cell Res. 15(9), 691-694 (2005
53. Broux B, Markovic-Plese S, Stinissen P, Hellings N. Pathogenic features of CD4+CD28-T cells in immune disorders. Trends Mol. Med. 18(8), 446-453 (2012
54. Parker TL, Strout MP. Chronic lymphocytic leukemia: Prognostic factors and impact on treatment. Discov. Med. 11(57), 115-123 (2011
55. Keysar SB, Jimeno A. More than markers: Biological significance of cancer stem cell-defining molecules. Mol. Cancer Ther. 9(9), 2450-2457 (2010
56. Venet F, Lepape A, Monneret G. Clinical review: Flow cytometry perspectives in the ICU-from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit. Care 15(5), 231 (2011
57. Schmitt F, Ricardo S, Vieira AF, Dionisio MR, Paredes J. Cancer stem cell markers in breast neoplasias: Their relevance and distribution in distinct molecular subtypes. Virchows Arch. 460(6), 545-553 (2012
58. Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 25(4), 535-548 (2011
59. Aggarwal A, Pyle J, Hamilton J, Bhat G. Low-dose rituximab therapy for antibody-mediated rejection in a highly sensitized heart-transplant recipient. Tex. Heart Inst. J. 39(6), 901-905 (2012
60. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J. Hematol. Oncol. 5, 64 (2012
61. Hanrahan JW, Tabcharani JA, Becq F et al. Function and dysfunction of the CFTR chloride channel. Soc. Gen. Physiol. Ser. 50, 125-137 (1995
62. Mccarthy MI, Abecasis GR, Cardon LR et al. Genome-wide association studies for complex traits: Consensus, uncertainty and challenges. Nat. Rev. Genet. 9(5), 356-369 (2008
63. Stranger BE, Stahl EA, Raj T. Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187(2), 367-383 (2011
64. Kelly TN, He J. Gene-sodium interaction and blood pressure: Findings from genomics research of blood pressure salt sensitivity. Prog. Mol. Biol. Transl. Sci. 108, 237-260 (2012
65. Maraganore DM, de Andrade M, Lesnick TG et al. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77(5), 685-693 (2005
66. Fung HC, Scholz S, Matarin M et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: First stage analysis and public release of data. Lancet Neurol. 5(11), 911-916 (2006
67. Nussbaum RL. Genome-wide association studies, Alzheimer disease, and understudied populations. JAMA 309(14), 1527-1528 (2013
68. Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl Acad. Sci. USA 106(25), 10338-10342 (2009
69. Basseville A, Bates SE. Gout, genetics and ABC transporters. F1000 Biol. Rep. 3, 23 (2011
70. Group SC, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008
71. Wilke RA, Ramsey LB, Johnson SG et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012
72. Stokes CS, Lammert F. Transporters in cholelithiasis. Biol. Chem. 393(1-2), 3-10 (2012
73. Garcia-Closas M, Ye Y, Rothman N et al. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum. Mol. Genet. 20(21), 4282-4289 (2011
74. Goodman SR, Kurdia A, Ammann L, Kakhniashvili D, Daescu O. The human red blood cell proteome and interactome. Exp. Biol. Med. (Maywood) 232(11), 1391-1408 (2007
75. Pasini EM, Lutz HU, Mann M, Thomas AW. Red blood cell (RBC) membrane proteomics-part I: Proteomics and RBC physiology. J. Proteomics 73(3), 403-420 (2010
76. Hernandez-Hernandez A, Rodriguez MC, Lopez-Revuelta A et al. Alterations in erythrocyte membrane protein composition in advanced non-small cell lung cancer. Blood Cells Mol. Dis. 36(3), 355-363 (2006
77. Koren W, Koldanov R, Pronin VS et al. Enhanced erythrocyte Na+/H+ exchange predicts diabetic nephropathy in patients with IDDM. Diabetologia 41(2), 201-205 (1998
78. Weder AB, Delgado MC, Zhu X, Gleiberman L, Kan D, Chakravarti A. Erythrocyte sodium-lithium countertransport and blood pressure: A genome-wide linkage study. Hypertension 41(3 Pt 2), 842-846 (2003
79. Sprague RS, Stephenson AH, Bowles EA, Stumpf MS, Lonigro AJ. Reduced expression of G(i) in erythrocytes of humans with Type 2 diabetes is associated with impairment of both cAMP generation and ATP release. Diabetes 55(12), 3588-3593 (2006
80. Antonelou MH, Kriebardis AG, Stamoulis KE, Trougakos IP, Papassideri IS. Apolipoprotein J/clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence. PLoS ONE 6(10), e26032 (2011
81. Saison C, Helias V, Ballif BA et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior. Nat. Genet. 44(2), 174-177 (2012
82. Kasza I, Varady G, Andrikovics H et al. Expression levels of the ABCG2 multidrug transporter in human erythrocytes correspond to pharmacologically relevant genetic variations. PLoS ONE 7(11), e48423 (2012
83. Kobayashi D, Ieiri I, Hirota T et al. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. 33(1), 94-101 (2005
84. Depirro R, Fusco A, Lauro R, Testa I, Ferreti F, Demartinis C. Erythrocyte insulin receptors in non-insulin-dependent diabetes mellitus. Diabetes 29(2), 96-99 (1980
85. Santos RF, Palmieri MG, Wajchenberg BL, Azhar S. Insulin-receptor tyrosine kinase activity is decreased in erythrocytes from non-obese patients with NIDDM. Horm. Metab. Res. 26(6), 283-287 (1994
86. Chapman K, Pullen N, Coney L et al. Preclinical development of monoclonal antibodies: Considerations for the use of non-human primates. MAbs 1(5), 505-516 (2009
87. Zola H. Medical applications of leukocyte surface molecules-the CD molecules. Mol. Med. 12(11-12), 312-316 (2006
88. Le Dantec C, Alonso R, Fali T et al. Rationale for treating primary Sjogren's syndrome patients with an anti-CD6 monoclonal antibody (itolizumab). Immunol. Res. 56(2-3), 341-347 (2013
89. Sethuraman C, Simmerson M, Vora AJ, Cohen MC. Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: How reliable is it and how can we optimize its use? J. Pediatr. Hematol. Oncol. 32(4), 298-303 (2010
90. Wozniak J. Two methods for the quantitative analysis of surface antigen expression in acute myeloid leukemia (AML). Folia Histochem. Cytobiol. 42(3), 195-199 (2004
91. Rusak M, Osada J, Pawlus J, Chociej-Stypulkowska J, Dabrowska M, Kloczko J. Utility of laboratory tests in B-CLL patients in different clinical stages. Int. J. Hematol. 93(6), 736-744 (2011
92. Sweet SC. Induction therapy in lung transplantation. Trans. Int. 26(7), 696-703 (2013
93. Waldmann TA. Immunotherapy: Past, present and future. Nat. Med. 9(3), 269-277 (2003